Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32675730 | 1.00 | HPGDS (0.48) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL22341404 | 0.94 | HPGDS (0.43) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL13697774 | 0.90 | HPGDS (0.49) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL1352085 | 0.88 | HPGDS (0.43) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL13271590 | 0.87 | SIRT6 (0.44) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL22133062 | 0.87 | HPGDS (0.42) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL15302247 | 0.87 | HPGDS (0.42) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL2159831 | 0.87 | HPGDS (0.42) | HPGDSFOLH1SLC15A2SLC6A5TLR2 | |
| SCHEMBL24451086 | 0.86 | HPGDS (0.35) | HPGDSFOLH1SLC15A2TLR2NOD1 | |
| SCHEMBL13363677 | 0.85 | SLC6A5 (0.56) | HPGDSFOLH1SLC6A5TLR2NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | claimed |
| US-12624068-B2 | Exon skipping by peptide nucleic acid derivatives | OLIPASS CORPORATION (KR) | 2026-05-12 | — | — | US | disclosed |
| EP-4696699-A1 | ? OPIOID RECEPTOR AGONIST AND USE THEREOF | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4251210-B1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S R L (IT) | 2025-03-19 | — | — | EP | disclosed |
| EP-4251211-B1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXIC DRUGS | ANBITION S R L (IT) | 2025-02-26 | — | — | EP | disclosed |
| EP-3603658-B1 | PEPTIDE FOR USE IN THE TREATMENT OF HEART FAILURE RESULTING FROM HYPERTROPHIC CARDIOMYOPATHY | UNIV CORNELL (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-3573645-B1 | ALPHA-MSH ANALOGUES USED IN THE TREATMENT OF XERODERMA PIGMENTOSUM | VALLAURIX MC S A R L (MC) | 2024-03-13 | — | — | EP | disclosed |
| EP-4302829-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4251211-A1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | Anbition S.r.l. (IT) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251210-A1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | Anbition S.r.l. (IT) | 2023-10-04 | — | — | EP | disclosed |
| EP-3513800-B1 | AROMATIC-CATIONIC PEPTIDE FOR USE IN THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME | UNIV CORNELL (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | Edinburgh Molecular Imaging Limited (GB) | 2022-09-01 | — | — | US | disclosed |
| WO-2022112865-A1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112866-A1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2022-06-02 | — | — | WO | disclosed |
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-1348714-B1 | Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use | COUNCIL SCIENT IND RES (IN) | 2007-01-03 | — | — | EP | disclosed |
| EP-1348714-A1 | Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | HIF1A, HIF1AN, UPF1 | HPGDS 377/4885FOLH1 890/4885SLC15A2 1867/4885 |
| US-12624068-B2 | Exon skipping by peptide nucleic acid derivatives | NSUN2, NSUN3, UPF1 | HPGDS 2241/4885FOLH1 1261/4885SLC15A2 1036/4885 |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | HPGDS 3430/4885FOLH1 1934/4885SLC15A2 1999/4885 |
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | VIP, QPCT, CALCRL | HPGDS 1365/4885FOLH1 17/4885SLC15A2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.